Kilitch Drugs (India) Limited has informed the Exchange regarding a press release dated May 22, 2025, titled "Q4FY25 Financial Results".
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kilitch Drugs announced strong Q4FY25 results with consolidated PAT rising 178% YoY to Rs. 1,021.86 lakh (from Rs. 368.07 lakh) and consolidated revenue growing 37% YoY to Rs. 6,122.58 lakh (from Rs. 4,481.88 lakh). On a standalone basis, Q4FY25 PAT surged 212% YoY to Rs. 1,137.41 lakh, while standalone revenue grew 44% YoY. For full-year FY25, standalone net profit jumped 77% YoY to Rs. 3,115.69 lakh and standalone revenue rose 38% YoY to Rs. 18,158.73 lakh. The company attributed growth to steady global demand and its focus on parenteral injectables, oral solids, and effervescent products. Kilitch is also setting up a new greenfield manufacturing project in Pen, Maharashtra, targeting USFDA-compliant production.
Strong double- and triple-digit growth in both revenue and profit signals robust operational momentum and could be viewed positively by the market, potentially supporting the stock price. Investors should note the numbers are unaudited and watch for the full audited results.